Company news

CelLBxHealth plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Lung cancer study uses ANGLE's Parsortix system

April 12, 2019

AACR 2019

April 4, 2019

Enrolment complete for FDA clinical study

March 7, 2019

First subjects enrolled in ovarian cancer study

February 28, 2019

Customer demonstrates new use for Parsortix

February 25, 2019

Research into role of immune cells in cancer

February 11, 2019

New application for Parsortix in cancer analysis

January 29, 2019

Breakthrough cancer research using Parsortix

January 10, 2019

Leading US hematopathologist appointed as advisor

November 28, 2018

Acquisition of outstanding shares

November 5, 2018

Appointment of Dr Jan Groen as NED

November 1, 2018

Parsortix shows capability to harvest fetal cells

October 29, 2018

Good Progress with FDA Studies

October 25, 2018

Parsortix shows evidence of CTCs in glioblastoma

August 28, 2018

Preliminary Results for year ended 30 April 2018

July 25, 2018

EIS/VCT Advance Assurance and Total Voting Rights

July 24, 2018

Notice of Preliminary Results

July 2, 2018

Results of Fundraising

June 25, 2018

Encouraging progress in ANG-002 FDA clinical study

June 4, 2018

Leading cancer surgeon appointed

May 14, 2018

Angle & QIAGEN Poster

May 3, 2018

Parsortix in multiple presentations at AACR

April 19, 2018

First patient enrolled in FDA study

April 5, 2018

Research Update

March 26, 2018

ANGLE plc: RESEARCH GRANT FROM ABBOTT

February 6, 2018

Webinar: using parsortix to test drugs on live CTCs

January 16, 2018

ANGLE plc: Prostate cancer ARV7 treatment biomarker

January 8, 2018

Transfer of Lock-in Shares

December 12, 2017

Parsortix potential in metastatic breast cancer

December 8, 2017

Parsortix enables CTC molecular characterisation

November 28, 2017

Philips collaboration in breast and rectal cancer

November 23, 2017

Total Voting Rights and Covington Subscription

November 16, 2017

ANGLE: Completion of Fundraising and Acquisition

November 1, 2017

Total Voting Rights

October 26, 2017

Parsortix harvests cancer cells from bone marrow

October 23, 2017

ANGLE: 7th Peer Reviewed Publication On Parsortix

October 17, 2017

Proposed further subscription for £2.8 million

October 12, 2017

CTCs harvested with Parsortix grown in laboratory

October 9, 2017

Acquisition and Fundraising

October 5, 2017

Exclusive worldwide option over megakaryocyte IP

September 13, 2017

Co-Marketing Partnership with QIAGEN

September 11, 2017

New Research with Parsortix

September 4, 2017

Preclinical Study Presented At Tumor Boston Summit

July 20, 2017

Successful Headline Data in Ovarian Cancer Studies

July 4, 2017

Parsortix breakthrough in prostate cancer

June 15, 2017

Success with Parsortix in Colorectal Cancer

June 5, 2017

Parsortix enables analysis in head and neck cancer

April 3, 2017

Prostate Cancer Update

March 30, 2017

Selected for European Cancer ID Programme

February 13, 2017

Interim Evaluation of Ovarian Cancer Study

January 26, 2017

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 30 decks. Every deck is listed under its year.